Cellectis S.A. Logo

Cellectis S.A.

Developing allogeneic CAR T-cell cancer immunotherapies using TALEN® gene-editing technology.

CLLS | NDAQ

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
United States of America
Address:
8 RUE DE LA CROIX JARRY, 0 PARIS, LLE-DE-FRANCE
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Cellectis S.A. is a clinical-stage biopharmaceutical company specializing in the development of cancer immunotherapies. The company leverages its proprietary gene-editing technology, TALEN®, to engineer Chimeric Antigen Receptor (CAR) T-cells. Cellectis focuses on creating allogeneic, or "off-the-shelf," CAR T-cell product candidates from healthy donor cells. This approach aims to provide broadly available and scalable treatments for a large number of patients, in contrast to personalized autologous therapies. The company's technology is designed to solve key challenges in allogeneic cell therapy, including Graft-versus-Host Disease (GvHD) and host-versus-graft rejection. Cellectis maintains a strong intellectual property portfolio and collaborates with global strategic partners to advance its therapeutic pipeline.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Cellectis S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cellectis S.A.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Cellectis S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Dermapharm Holding SE Logo
Manufactures patent-free branded pharmaceuticals & healthcare products for niche markets.
Germany DMP
Dermata Therapeutics, Inc. Logo
Develops OTC skin treatments using a unique delivery technology from freshwater sponges.
United States of America DRMA
Design Therapeutics, Inc. Logo
Develops small molecule genomic medicines to treat serious genetic diseases by modulating genes.
United States of America DSGN
Deutsche Biotech Innovativ AG Logo
Develops biomarker-driven therapeutics and diagnostics for serious diseases with unmet needs.
Germany DBI
DEVA HOLDİNG A.Ş. Logo
Global manufacturer of human/veterinary pharmaceuticals, APIs, and medical ampoules.
Spain DEVA
Devyser Diagnostics Logo
Develops & sells genetic DNA test kits for labs in oncology, transplant & reproductive health.
Sweden DVYSR
DiaMedica Therapeutics Inc. Logo
Developing a novel protein therapy for acute ischemic stroke and preeclampsia.
United States of America DMAC
Diamyd Medical AB (publ) Logo
Developing precision immunotherapies to preserve insulin in autoimmune diabetes.
Sweden DMYD
Dianthus Therapeutics, Inc. /DE/ Logo
Developing selective antibody therapies for severe autoimmune diseases.
United States of America DNTH
Diasorin Logo
Develops immunodiagnostic and molecular diagnostic kits and systems for healthcare and research.
Italy DIA

Talk to a Data Expert

Have a question? We'll get back to you promptly.